Showing 401 - 420 results of 65,858 for search '(( 5 we decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.12s Refine Results
  1. 401
  2. 402
  3. 403
  4. 404

    Image 2_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  5. 405

    Table 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.xlsx by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  6. 406

    Image 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  7. 407

    Data_Sheet_1_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

    Published 2022
    “…In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. …”
  8. 408
  9. 409

    Image_5_Catheter-Based Therapies Decrease Mortality in Patients With Intermediate and High-Risk Pulmonary Embolism: Evidence From Meta-Analysis of 65,589 Patients.TIF by Arkadiusz Pietrasik (12879863)

    Published 2022
    “…Background<p>Catheter-directed therapies (CDT) are an alternative to systemic thrombolysis (ST) in pulmonary embolism (PE) patients, but the mortality benefit of CDT is unclear.</p>Objective<p>We conducted a systematic review with meta-analysis to compare the efficacy and safety of CDT and ST in intermediate-high and high-risk PE.…”
  10. 410
  11. 411
  12. 412
  13. 413
  14. 414

    Table_1_Soil Properties Interacting With Microbial Metagenome in Decreasing CH4 Emission From Seasonally Flooded Marshland Following Different Stages of Afforestation.xlsx by Qian Zhang (49333)

    Published 2022
    “…Compared to the non-afforested land use types, net CH<sub>4</sub> emission decreased from bare land, natural vegetation and 5-year forest plantation and transitioned to net CH<sub>4</sub> sinks in the 10- and 20-year forest plantations. …”
  15. 415

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  16. 416
  17. 417
  18. 418

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  19. 419
  20. 420